An observational study in Overweight and Obesity, sponsored by Novo Nordisk A/S. Completed at 6 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Novo Nordisk A/S · Observational
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 210 studies in Obesity by Novo Nordisk A/S — 51 open to participants now, 69 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.
Among the 210 studies in Obesity by Novo Nordisk A/S, this one is the 21st largest by enrollment of the 41 observational ones that give a count, is one of 50 that started in 2026, is one of 41 observational ones, and was the 202nd registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →51 of the 210 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in Austria
Ages 18–64
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18+
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
210 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 15 · Phase 3 62 · Phase 4 4
First in 2007; this study’s year is marked. 50 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,260 is above the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 134 across the 169 interventional studies, 1,260 across the 41 observational. Of the 138 that completed or were terminated, 39 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
26 of the studies in Obesity by Novo Nordisk A/S that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011667Phase 3Novo Nordisk A/SA Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | 2027-03-01 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07745504Phase 3Novo Nordisk A/SA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | 2027-05-18 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
Add all 26 to your calendar (.ics) → With an account.
Among the 210 studies in Obesity by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess semaglutide's impact on daily life from participants and physicians experience.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
This study's enrollment of 1,260 is above the median of 115 across 2,159 observational studies indexed under Obesity.
Browse Obesity studies →Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Participants receiving semaglutide for at least 16 weeks are included for secondary database analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- This is a secondary database analysis
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients included in this study were those who had been diagnosed with overweight or obesity and had been initiated on Wegovy (semaglutide) at least 16 weeks prior to the date the DSP survey was conducted. This study is based on a retrospective analysis of existing physician-reported data collected through the DSP survey.
Drug: Semaglutide
This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study.
Change in Food Noise Questionnaire (FNQ) score
Food noise assessed retrospectively prior to Wegovy initiation and at data capture using the Food Noise Questionnaire (FNQ). The questionnaire evaluates intrusive and persistent food-related thoughts. Each item is scored 0-5, with a total score range of 0-20. Higher scores indicate greater food noise
Time frame: At data capture (Day 1)
Change in Body Weight
Change in body weight (kg) from initiation of Wegovy to data capture. Weight measured prior to Wegovy initiation and at data collection.
Time frame: At data capture (Day 1)
Health-Related Quality of Life Measured by EQ-5D-5L
Health-related quality of life assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) index score. The EQ-5D-5L consists of 5 items rated on a 5-point Likert scale that ranges from 1 (no problems) to 5 (extreme problems). Higher index scores indicate better health-related quality of life.
Time frame: At data capture (Day 1)
Health Status Measured by EQ Visual Analogue Scale (EQ-VAS)
Participant-rated overall health status measured using the EQ-VAS. Scores range from 0 to 100, where higher scores indicate better perceived health.
Time frame: At data capture (Day 1)
Medication Adherence Measured by Adelphi Adherence Questionnaire (ADAQ)
Participant-reported adherence to Wegovy treatment assessed using the Adelphi Adherence Questionnaire (ADAQ). The overall adherence summary score ranges from 0 to 4, with lower scores indicating greater medication adherence.
Time frame: At data capture (Day 1)
Number of Participant Satisfaction With Wegovy
Participant satisfaction with Wegovy treatment assessed as less than satisfied, satisfied, or more than satisfied according to perceived treatment performance relative to expectations.
Time frame: At data capture (Day 1)
Change in Body Mass Index (BMI)
Change in body mass index (kg/m²) from Wegovy initiation to data capture will be reported
Time frame: At data capture (Day 1)
Percent Change in Body Weight
Percentage change in body weight between Wegovy initiation and data capture will be reported.
Time frame: At data capture (Day 1)
Number of Participants with Achievement of Weight-Loss Target
Participant-reported achievement of the predefined weight-loss goal (Yes/No). Participants may be classified as having reached or exceeded their target weight loss.
Time frame: At data capture (Day 1)
Number of Participants who Concern About Future Weight Gain
Number of Participant concern regarding regaining weight after discontinuation of Wegovy treatment will be reported.
Time frame: At data capture (Day 1)
Impact of Wegovy on Weight-Related Burden
Degree to which participants were bothered by their weight before starting Wegovy and at data capture after receiving Wegovy.
Time frame: At data capture (Day 1)
Impact of Wegovy on Daily Life and Health Behaviours
Changes in work-life impact, cigarette smoking, shisha smoking, and alcohol consumption since initiation of Wegovy.
Time frame: At data capture (Day 1)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Ran from Aug 2026 to primary completion in Aug 2026, 0 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.